DeRisio Richard J. 4
4 · ABBOTT MEDICAL OPTICS INC · Filed Feb 27, 2009
Insider Transaction Report
Form 4
DeRisio Richard J.
Corporate Vice President
Transactions
- Award
Common Stock
2009-02-25+3,000→ 3,000 total - Disposition to Issuer
Common Stock
2009-02-26$22.00/sh−1,927$42,394→ 0 total - Award
Common Stock
2009-02-25+2,500→ 2,500 total - Disposition to Issuer
Employee Stock Option (Right to Buy)
2009-02-26−10,860→ 0 totalExercise: $22.94From: 2009-02-25Exp: 2018-05-29→ Common Stock (10,860 underlying) - Disposition to Issuer
Common Stock
2009-02-26$22.00/sh−1,606$35,332→ 0 total - Disposition to Issuer
Employee Stock Option (Right to Buy)
2009-02-26−21,000→ 0 totalExercise: $30.15From: 2009-02-25Exp: 2017-08-27→ Common Stock (21,000 underlying) - Award
Common Stock
2009-02-25+4,500→ 4,500 total - Tax Payment
Common Stock
2009-02-25$22.01/sh−1,609$35,414→ 2,891 total - Disposition to Issuer
Common Stock
2009-02-26$22.00/sh−2,891$63,602→ 0 total - Tax Payment
Common Stock
2009-02-25$22.01/sh−1,073$23,617→ 1,927 total - Tax Payment
Common Stock
2009-02-25$22.01/sh−894$19,677→ 1,606 total
Footnotes (4)
- [F1]The exempt restricted stock units (previously reported on Table II) vested in full and were settled for shares of Issuer Common Stock in accordance with the terms of the applicable equity plan. At the effective time of the merger (defined in the Agreement and Plan of Merger dated January 11, 2009, by and among Abbott Laboratories, Rainforest Acquisition Inc. and the Issuer ("Merger Agreement"), such shares were cancelled pursuant to the Merger Agreement in exchange for the right to receive cash payment of $22.00 per share in cash (without interest and subject to any required withholding taxes).
- [F2]Shares withheld in satisfaction of tax obligations attributable to the lapse of restrictions on stock award or in satisfaction of tax withholding attributable to vesting and settlement of restricted stock units.
- [F3]This previously reported exempt stock option, which was to have vested ratably over the first four years from the date of grant, will be exchanged for a fully vested stock option issued by Abbott Laboratories to purchase 8,616 shares of Abbott Laboratories common stock at an exercise price of $73.49 per share, determined pursuant to a formula set forth in the Merger Agreement.
- [F4]This previously reported exempt stock option, which was to have vested ratably over the first four years from the date of grant, will be exchanged for a fully vested stock option issued by Abbott Laboratories to purchase 4,455 shares of Abbott Laboratories common stock at an exercise price of $55.92 per share, determined pursuant to a formula set forth in the Merger Agreement.